Immix Biopharma, Inc.
IMMX
$8.18
$0.172.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -122.10% | -6.10% | -50.76% | 13.62% | 5.45% |
| Total Depreciation and Amortization | 119.37% | 420.85% | 228.40% | 147.70% | 1,232.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -19.12% | -35.88% | -14.83% | -0.32% | -28.35% |
| Change in Net Operating Assets | -138.75% | -54.34% | 146.33% | 259.30% | 81.80% |
| Cash from Operations | -647.16% | -46.32% | -1.02% | 55.97% | 44.86% |
| Capital Expenditure | 67.45% | -37.20% | -31.41% | 77.58% | -3,742.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,210.33% | -37.20% | -31.41% | 77.58% | -3,742.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | 53.39% | -189.57% | 395.51% | 23.08% | -180.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,982.56% | 200.58% | 19.85% | -114.91% | 3.09% |